Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0DDTZB
ADC Name
HLX-43
Synonyms
HLX 43; HLX-43; HLX43; YL222
   Click to Show/Hide
Organization
Shanghai Henlius Biotech, Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Drug Status
Phase 2
Indication
In total 6 Indication(s)
Cervical cancer
Phase 2
Clinical Trial
Head and neck cancer
Phase 2
Clinical Trial
Liver cancer
Phase 2
Clinical Trial
Nasopharyngeal cancer
Phase 2
Clinical Trial
Oesophageal cancer
Phase 2
Clinical Trial
Solid tumor
Phase 1
Clinical Trial
Drug-to-Antibody Ratio
8
Antibody Name
HLX20
  Antibody Info 
Antigen Name
Programmed cell death 1 ligand 1 (CD274)
  Antigen Info 
Payload Name
Camptothecin-based toxin
  Payload Info 
Therapeutic Target
DNA topoisomerase 1 (TOP1)
  Target Info 
Conjugate Type
Undisclosed